Format

Send to

Choose Destination
Australas Psychiatry. 2016 Dec;24(6):541-544. Epub 2016 Aug 24.

Severe motor and vocal tics controlled with Sativex®.

Author information

1
Psychiatry Registrar, Department of Psychiatry, Tauranga Hospital, Tauranga, New Zealand.
2
Consultant Psychiatrist, Department of Psychiatry, Tauranga Hospital, Tauranga, New Zealand rupert.bird@bopdhb.govt.nz.

Abstract

OBJECTIVES:

A single case report on cannabinoid treatment for treatment-resistant Tourette syndrome (TS).

METHOD:

Our subject received 10.8 mg Tetrahydocannabinol and 10 mg cannabidiol daily, in the form of two oro-mucosal sprays of 'Sativex®', twice daily. Assessment was pre-treatment and at week one, two, and four during treatment. He completed the Yale Global Tic Severity Scale as a subjective measure, and was videoed at each stage. The videos were objectively rated by two assessors, blind to the stage of treatment, using the Original Rush Videotape Rating Scale.

RESULTS:

Both subjective and objective measures demonstrated marked improvement in the frequency and severity of motor and vocal tics post-treatment. There was good interrater reliability of results.

CONCLUSIONS:

Our results support previous research suggesting that cannabinoids are a safe and effective treatment for TS and should be considered in treatment-resistant cases. Further studies are needed to substantiate our findings.

KEYWORDS:

Sativex®; Tetrahydrocannabinol; cannabis; tourette syndrome

PMID:
27558217
DOI:
10.1177/1039856216663737
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center